Last $14.15 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (OMER) Snapshot

Open
$14.12
Previous Close
$14.15
Day High
$14.42
Day Low
$13.98
52 Week High
07/2/14 - $18.80
52 Week Low
08/30/13 - $4.95
Market Cap
481.0M
Average Volume 10 Days
276.8K
EPS TTM
$-1.86
Shares Outstanding
34.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (OMER)

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its clinical products include Omidria, which has completed two Phase III clinical trials for use during intraocular lens replacement, including cataract and other lens replacement surgery; OMS103 that is in Phase III clinical program for use during arthroscopic procedures, such as partial meniscectomy surgery; and OMS824, which is in Phase II clinical trial for the treatment of CNS disorders comprising schizophrenia and Huntington's disease. Its clinical programs also consist of OMS721 that is in Phase II clinical trial for the treatment of various complement-related diseases and disorders, including thrombotic microangiopathies; OMS405, which is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase 1/Phase 2 clinical trial for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical products and development programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; and OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions. Its preclinical products also include G protein-coupled receptors platform for multiple disorders across therapeutic area; GPR17 for demyelinating disorders; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $664.6K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $79.7K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2013.

omeros corp (OMER) Key Developments

Omeros Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Omeros Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter ended June 30, 2014, Omeros reported a net loss of $18.0 million, or $0.53 per share. This compares to a net loss of $13.6 million or $0.48 per share, for the same period in 2013. Revenue for the quarter ended June 30, 2014 was $45,000 compared to $140,000 for the same period in 2013. This decrease was due to a reduction of activity on NIH grant projects, which resulted in lower revenue being recognized. Loss from operations was $17.217 million against $13.160 million a year ago. For the six-month period, the company reported revenues were $0.145 million against $1.235 million a year ago. Loss from operations was $32.901 million against $23.180 million a year ago. Net loss was $34.633 million or $1.07 basic and diluted per share against $24.081 million or $0.89 basic and diluted per share a year ago.

Omeros Corporation Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 12:45 PM

Omeros Corporation Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 12:45 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Gregory A. Demopulos, Co-Founder, Chairman, Chief Executive Officer and President.

Omeros Corporation Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 03:00 PM

Omeros Corporation Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 03:00 PM. Venue: Washington State Convention Center, Seattle, Washington, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $14.15 USD 0.00

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
No financial data is available for OMER.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.